This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the CKD Anemia market through 2034.
There will be an overall increase in the diagnosed prevalent cases of CKD Anemia in the 7MM across the forecast period.
Across the 7MM, the mainstay treatment for CKD Anemia involves the use of ESAs and iron therapies.
Significant clinical and environmental unmet needs remain in the CKD Anemia market.
The late-stage CKD anemia pipeline consists of 2 agents.
The CKD Anemia market in the 7MM was valued at $4.4 billion in 2024. The market is projected to grow at a CAGR of 1.7%, reaching $5.3 billion by 2034.
There will be an overall increase in the diagnosed prevalent cases of CKD Anemia in the 7MM across the forecast period.
Across the 7MM, the mainstay treatment for CKD Anemia involves the use of ESAs and iron therapies.
Significant clinical and environmental unmet needs remain in the CKD Anemia market.
The late-stage CKD anemia pipeline consists of 2 agents.
The CKD Anemia market in the 7MM was valued at $4.4 billion in 2024. The market is projected to grow at a CAGR of 1.7%, reaching $5.3 billion by 2034.
Scope
- Overview of CKD anemia, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized CKD anemia therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2024 and forecast for 10 years to 2034.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CKD anemia therapeutics market.
- Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for CKD anemia treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 7MM CKD anemia therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CKD anemia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CKD anemia therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1. Preface
3. Disease Overview
4. Epidemiology
5. Current Treatment Options
6. Unmet Needs and Opportunities
7. R&D Strategies
8. Pipeline Assessment
9. Market Outlook
10. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen
- Kyowa Kirin
- Janssen
- Vifor Pharma
- Roche
- Chugai Pharmaceutical
- Teva
- Akebia
- Torii Pharma
- American Regent
- Sanofi
- Sandoz
- Pharmacosmos
- Allergan
- Shield TX
- Norgine BV
- AstraZeneca
- Fibrogen
- Astellas Pharma
- Mitsubishi Tanabe
- GSK
- Bayer Yakuhin
- Japan Tabacco
- PT Kalbe Genexine Biologics
